Gujarat Themis Biosyn Q1 Results Reported Revenue of ₹3,935.17 lakhs and Net Profit of ₹1,323.62 lakhs

Gujarat Themis Biosyn Q1 Results 2024 - 2025: Gujarat Themis Biosyn announced their Q1 results for the 2024-2025 fiscal year on July 26, 2024. The company reported a revenue of ₹3,935.17 lakhs for the quarter ending June 30, 2024, showing a decrease of 8.6% compared to the ₹4,302.97 lakhs recorded in the previous quarter.

This decline in income is attributed to a slight dip in operational income, despite a modest increase in other income sources. In terms of profitability, Gujarat Themis Biosyn's net profit for Q1 2024-2025 was ₹1,323.62 lakhs, marking a decrease of 16.7% from the ₹1,588.56 lakhs achieved in the previous quarter.

The drop in profit was influenced by higher operational expenses, including a rise in depreciation costs. Despite these challenges, the company's performance remains strong, reflecting its ongoing efforts to manage costs and optimize operations.

For More Q1 results check our Twitter Page

Gujarat Themis Biosyn Q1 Results 2024 - 2025

Here’s a summary of Gujarat Themis Biosyn's Q1 results for the fiscal year 2024-2025:

Source: Click Here

Gujarat Themis Biosyn Current Market Overview

Gujarat Themis Biosyn is currently trading at ₹345 per share, down by 1.96%. The company has a market capitalization of ₹3,759 crore, reflecting its total value in the stock market. The stock has seen a high of ₹390 and a low of ₹103 over its recent trading period.

With a P/E ratio of 68.8, the stock is considered relatively expensive compared to its earnings. It has a book value of ₹18.5 per share and offers a modest dividend yield of 0.19%. The company shows strong financial performance with a return on capital employed (ROCE) of 45.0% and a return on equity (ROE) of 33.8%.

Quarterly Results

Here are the quarterly results for Gujarat Themis Biosyn for the last three quarters:

About Gujarat Themis Biosyn 

Gujarat Themis Biosyn is a pharmaceutical company based in India. Established in 1981 as a joint venture with GIIC Ltd. and Chemosyn (P) Ltd., it began production in 1985. In 1991, the company was acquired by South Korea’s Yuhan Group and a consortium of Indian drug companies, including Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd., and Lyka Labs Ltd.

Since 2007, Themis Medicare Ltd., a joint venture with Gedeon Richter Ltd. from Hungary, has actively managed the company. Gujarat Themis Biosyn focuses on manufacturing and providing a range of pharmaceutical products, contributing significantly to the healthcare industry.

Check our website for more Q1 results.